{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n LIX1L is emerging as a multifaceted protein in cancer and liver disease biology. It is a putative RNA‐binding protein with a double‐stranded RNA binding motif that is highly expressed in various tumors. In hepatocellular carcinoma (HCC), for example, LIX1L upregulation—mediated by a lncRNA/miRNA axis (with TATDN1 degrading miRNA‐6089)—promotes cell proliferation and accelerates cell cycle progression, implicating LIX1L as a facilitator of tumor growth."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " In addition, biochemical studies have shown that phosphorylation of LIX1L at Tyr136 is crucial for its pro‐proliferative functions, as reducing this phosphorylation significantly dampens cancer cell proliferation."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Beyond proliferation, LIX1L has been linked to changes in cellular phenotype; its elevated expression is associated with a mesenchymal signature and enhanced cellular migration and invasiveness, suggesting that LIX1L might contribute to tumor aggressiveness."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": " Moreover, studies focusing on liver pathology reveal that LIX1L plays a role in cholestatic liver injury. In this setting, bile acid–stimulated upregulation of LIX1L—dependent on the transcription factor Egr‑1—promotes bile acid synthesis through a regulatory nexus involving miR‑191‑3p and LRH‑1 signaling; experimental LIX1L deficiency in murine models alleviates liver injury."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Finally, clinical data indicate that LIX1L is over‑expressed in human HCC tissues and its high expression correlates with an unfavorable prognosis. Complementary computational analyses predict LIX1L as a target of miR‑1269 in HCC, further implicating it in tumorigenesis."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Together, these studies underscore a complex role for LIX1L as a modulator of post‐transcriptional gene regulation, with significant impacts on cell proliferation, migration, metabolic regulation, and overall tumor progression. This makes LIX1L a promising candidate for therapeutic intervention in cancer and bile acid–associated liver diseases.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "C Shen, Y Xu, T-F Lu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LncRNA TATDN1 induces the progression of hepatocellular carcinoma via targeting miRNA-6089."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur Rev Med Pharmacol Sci (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.26355/eurrev_201908_18529"}], "href": "https://doi.org/10.26355/eurrev_201908_18529"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31378885"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31378885"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Satoki Nakamura, Tomoaki Kahyo, Hong Tao, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Novel roles for LIX1L in promoting cancer cell proliferation through ROS1-mediated LIX1L phosphorylation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Sci Rep (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/srep13474"}], "href": "https://doi.org/10.1038/srep13474"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26310847"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26310847"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Peter Rotwein "}, {"type": "b", "children": [{"type": "t", "text": "Variation in the repulsive guidance molecule family in human populations."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Physiol Rep (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.14814/phy2.13959"}], "href": "https://doi.org/10.14814/phy2.13959"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30746893"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30746893"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Jie Li, Xiaoyun Zhu, Meihui Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Hepatol (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.jhep.2021.02.035"}], "href": "https://doi.org/10.1016/j.jhep.2021.02.035"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33746084"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33746084"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Ting-Qing Gan, Rui-Xue Tang, Rong-Quan He, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Upregulated MiR-1269 in hepatocellular carcinoma and its clinical significance."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Clin Exp Med (2015)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25785048"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25785048"}]}]}]}